Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 39

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

Targeting hypoxia and mitochondrial metabolism with repurposing drugs as an ...

Abstract Diffuse intrinsic pontine glioma (DIPG) is a rare and incurable brain tumor that arises in the brainstem of children predominantly between the ages of 6 and 9.  Unlike many brain tumors, DIPGs cannot be removed through surgery due to its sensitive location. The standard of care today remains radiation therapy (...

A novel CRISPR/Cas9 approach to target the EWS-FLI1 fusion ...

Ewing’s sarcoma (EWS) is a devastating pediatric cancer of bone and soft tissues where the treatments used are typically very toxic, resulting in profound morbidities. Furthermore, these intense and non-specific treatments often lead to secondary tumors later in life. Thus, a less toxic and more specific treatment is ...

Multi-modal Epigenetic Pt(IV) Prodrugs for Paediatric High Grade Gliomas

Diffuse intrinsic pontine gliomas (DIPG) are highly aggressive cancers - DIPG has a survival rate of 1% at 5 years. Platinum(II) anti-cancer drugs (e.g. carboplatin) are used in combination with sodium valproate to treat DIPG clinically, with the intact blood brain barrier being effectively bypassed by convection enhanced delivery. We ...

Precision Therapy to Overcome Chemoresistance in Pediatric Glioblastoma

Glioblastoma (GBM) remains one of the most aggressive and lethal forms of cancer. Despite the best available treatment options including surgical resection, radiotherapy, and chemotherapy, prognosis is poor in glioblastoma, with a median overall survival of 14 months.1Currently, temozolomide (TMZ) is the preferred chemotherapeutic drug in the treatment of GBM ...